Pfizer Inc. and BioNTech SE announced they have reached an agreement with the European Commission (EC) to amend their existing contract to deliver COVID-19 vaccines to the European Union. The amended agreement reflects the companies' commitment to working collaboratively to help address ongoing public health needs, while respecting the principles of the original agreement. It includes rephasing of delivery of doses annually through 2026.

In addition, the agreement includes an aggregate volume reduction, providing additional flexibility for EU Member States.